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Abstract
Objective: Several studies report a polygenic component of risk for Alzheimer’s disease.
Understanding whether this polygenic signal is associated with educational, cognitive
and behavioural outcomes in children could provide an earlier window for intervention.
Methods: We examined whether polygenic risk scores (PRS) at varying P-value thresh-
olds in children from the Avon Longitudinal Study of Parents and Children were associ-
ated with academic achievement, cognitive and behavioural measures in childhood and
adolescence.
Results: We did not detect any evidence that the genome-wide significant PRS (5x10-8)
were associated with these outcomes. PRS at the highest P-value threshold examined
(P5x10-1) were associated with lower academic achievement in adolescents (Key Stage
3; b: -0.03; 95% confidence interval: -0.05, -0.003) but the effect was attenuated when single
nucleotide polymorphisms (SNPs) associated with educational attainment were removed.
These PRS were associated with lower IQ (b: -0.04; 95% CI: -0.07, -0.02) at age 8 years with
the effect remaining after removing SNPs associated with educational attainment.
Conclusions: SNPs mediating the biological effects of Alzheimer’s disease are unlikely to
operate early in life. The evidence of association between PRS for Alzheimer’s disease at
liberal thresholds and cognitive measures suggest shared genetic pathways between
Alzheimer’s disease, academic achievement and cognition.
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Introduction
Alzheimer’s disease is a heritable neurodegenerative disease
which, in addition to other dementia forms, affects 47 million
individuals worldwide.1 The long prodromal phase is charac-
terized by cognitive decline and behavioural disturbances.2,3
As Alzheimer’s disease exerts a heavy socioeconomic bur-
den,4 identifying modifiable factors earlier in life is important
for preventing or delaying the onset of the disease.
Genome-wide association studies (GWAS)5 have identi-
fied several single nucleotide polymorphisms (SNPs) asso-
ciated with late-onset Alzheimer’s disease, all exerting low
to modest effects [except for the e4 allele in the apolipopro-
tein E (ApoE) gene)].6,7 The effects of common genetic risk
variants for complex diseases, including Alzheimer’s dis-
ease, can be considered en masse to calculate a polygenic
risk score (PRS) for disease.8–10 These scores can be used
as an indicator of genetic risk for Alzheimer’s disease (irre-
spective of whether an individual will develop Alzheimer’s
disease) to investigate the genetic overlap between
Alzheimer’s disease and other diseases or traits. The overall
SNP heritability of Alzheimer’s disease (24–35%) identi-
fied in GWAS11 is higher when SNPs of small effect size
are also considered, indicating that there are many SNPs
below the genome-wide level of significance contributing
to increasing genetic risk for Alzheimer’s disease.8
Pathophysiological changes resulting in gradual cognitive
and functional decline can occur more than two decades be-
fore the onset of clinical symptoms.12,13 This presents a chal-
lenge in the development of effective treatments and highlights
the need for intervention preceding the initiation of the disease
process. There is an established association between PRS for
Alzheimer’s disease, cognitive outcomes and educational at-
tainment in adults.14–16 However, the association between ac-
ademic achievement, as well as cognitive outcomes, and
behavioural difficulties in young ages is understudied.
In our study, we investigated whether a PRS for
Alzheimer’s disease is associated with academic achievement
at Key Stages 3, 4 and 5, childhood IQ at 8 and 15 years and
behavioural difficulties at 9 and 12 years using a large popu-
lation sample.
Methods
Participants
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a prospective birth cohort study which
recruited pregnant women residing in the former Avon
Health Authority area with expected delivery dates be-
tween April 1991 and December 1992; 14 541 pregnant
women were initially enrolled, with 14 062 children born.
A detailed description of the cohort has been published
previously.17,18 Detailed information on health and devel-
opment of children and their parents was collected from
regular clinic visits and completion of questionnaires.
The study website contains details of all the data that are
available through a fully searchable data dictionary [http://
www.bris.ac.uk/alspac/researchers/data-access/data-dictio
nary/]. Ethical approval was obtained from the
ALSPAC Law and Ethics Committee and the local ethics
committees.
ALSPAC genetic data
A total of 9912 ALSPAC children were genotyped on the
Illumina HumanHap550-quad SNP genotyping platform.
After quality control (QC) assessment published else-
where,19,20 imputation and restriction to one child per
family, genetic data were available for 7977 individuals
(QC procedures in Supplementary material, available as
Supplementary data at IJE online).
Polygenic Risk Scores
PRS were computed according to the method described
by the International Schizophrenia Consortium10 based on
Key Messages
• This is the first time that the effect of genetic variants for Alzheimer’s disease on academic achievement, cognitive
and behavioural measures are being investigated in a large sample of children.
• Genetic variants most strongly associated with Alzheimer’s disease are not associated with any of examined
outcomes.
• Alzheimer’s disease may share genetic pathways with cognition and academic achievement, as indicated by findings
at liberal P-value thresholds.
• Individuals with substantially increased risk of Alzheimer’s disease later in life have similar academic achievement to
other individuals in the population.
• Our study suggests that the preclinical effects for Alzheimer’s disease are unlikely to operate in childhood.
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the summary statistics from the GWAS of Alzheimer’s dis-
ease by the IGAP consortium.5 Details about IGAP and
PRS are in the Supplementary material, available as
Supplementary data at IJE online. Our main analysis
focused on P-value thresholds P5x10-8, 5x10-2 and
5x10-1, although more thresholds were tested
(Supplementary material, available as Supplementary data
at IJE online). The number of SNPs in the PRS at each
P-value threshold is provided in Supplementary Table 1,
available as Supplementary data at IJE online. A list of 19
SNPs used to generate the PRS at the genome-wide signifi-
cant threshold is provided in Table 1.
Measures
Academic achievement
Academic achievement measures were attained through
linkage to compulsory UK educational assessments from
the National Pupil Database21 and were evaluated at three
time points during the pupils’ education; Key Stages 3, 4
and 5. Key Stage 3 national tests are taken when children
are 14 years old and include English, Mathematics and
Science assessments. For Key Stage 4, General Certificate
of Secondary Education (GCSE) examinations determine
transition into post-compulsory education. Students study
up to 12 subjects (eight on average) of which some are
compulsory (e.g. English and Mathematics). The Key Stage
4 scores were analysed as the total point score, which is
capped at the student’s eight best GCSE (and equivalent)
qualifications.22 For Key Stage 5, examinations are taken
when the students are 18 years old (A levels) and range
from A* to E. Test scores at all Key Stages were provided
as a scaled total points score. A binary variable was gener-
ated to investigate whether PRS was associated with pro-
gression to Key Stage 5 tests for children with available
GCSE results.
Intelligence quotient
Total IQ scores were collected when children were 8 years
old, using the computerized version of the Wechsler
Intelligence Scale for Children (WISC-III).23 Verbal and
performance subtests were administered, their scores were
scaled to age, and the total IQ scores derived. At 15 years,
children were administered the Vocabulary and Matrix
Reasoning subcategories of the Wechsler Abbreviated
Scale of Intelligence (WASI).24 The verbal, performance
and total IQ scores are normative IQs, with a mean of 100
and a standard deviation of 15.24 Mean IQ differed from
age 8 (IQ¼ 105.0) to age 15 (IQ¼ 92.4). A thorough in-
vestigation was carried out by ALSPAC, and it was con-
cluded that there were no systematic errors in the way the
WASI (or the WISC) was scored. These tests are designed
for different age ranges and cannot be interpreted inter-
changeably or to reflect change over time.25
Behavioural problems
Behavioural problems in childhood were measured by the
Strengths & Difficulties Questionnaire (SDQ),26 completed
by mothers when the children were 9 and 12 years old.
More details on SDQ can be found in Supplementary
Table 1. SNPs included in PRS with a genome-wide significance threshold as reported in IGAP stage 1
Marker Chromosome Position Nearest gene A1 A2 OR
rs6656401 1 207692049 CR1 A G 1.17
rs6733839 2 127892810 BIN1 T C 1.21
rs35349669 2 234068476 INPP5D T C 1.07
rs190982 5 88223420 MEF2C G A 0.92
rs10948363 6 47487762 CD2AP G A 1.10
rs2718058 7 37841534 NME8 G A 0.93
rs1476679 7 100004446 ZCWPW1 C T 0.92
rs11771145 7 143110762 EPHA1 A G 0.90
rs28834970 8 27195121 PTK2B C T 1.10
rs10838725 11 47557871 CELF1 C T 1.08
rs983392 11 59923508 MS4A6A G A 0.90
rs10792832 11 85867875 PICALM A G 0.88
rs11218343 11 121435587 SORL1 C T 0.76
rs17125944 14 53400629 FERMT2 C T 1.13
rs10498633 14 92926952 SLC24A4 T G 0.90
rs4147929 19 1063443 ABCA7 A G 1.14
rs429358/rs7412 19 45411941/45412079 APOE e4 e2/3 3.86/1.47
rs7274581 20 55018260 CASS4 C T 0.87
Additional information provided: chromosomal and base pair position, nearest gene, minor allele (A1) and major allele (A2), odds ratio (OR).
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material, available as Supplementary data at IJE online.
Due to the skewed nature of the SDQ variables (with most
children demonstrating no problems), the five SDQ sub-
scales were dichotomized as in previous studies.27,28
Examining the association between the PRS and the
outcomes
Linear and ordinary logistic regression models were used for
continuous and categorical outcomes, respectively. For the
cognitive outcomes (IQ, academic achievement), z-scores
were calculated to enable comparison of the magnitude of
regression coefficients across outcomes and time points.
Models were adjusted for age, sex and the first three
ancestry-informative principal components (Model 1).
Analyses were performed in Stata 14.29 As the outcome
measures are highly interdependent, we used principal com-
ponent analysis (PCA) to extract factors, using a cut-off
threshold of an eigenvalue of 1 (Kaiser rule).30 Our results
were interpreted according to the American Statistical
Association guidance,31,32 by presenting raw summary statis-
tics and using PCA to assist with interpreting our findings.
Sensitivity analysis
Results from Model 1 were compared with those based on
scores that excluded SNPs within the ApoE gene (Chr. 19:
44 400–46 500 kb) (Model 2) due to the large effect sizes
within that region, which may have been driving any ob-
served associations. They were also compared with scores
including the two SNPs tagging the ApoE gene (rs7412
and rs429358) (Supplementary material, available as
Supplementary data at IJE online) (Model 3). To exclude
the possibility that the effect of the PRS on academic
achievement and cognitive outcomes is driven by SNPs
associated with educational attainment, we repeated the
analysis with a PRS excluding SNPs associated with educa-
tional attainment. at P 5x10-8 and at P 5x10-2.
The number of SNPs removed at each PRS P-value thresh-
old is provided in Supplementary Table 2, available as
Supplementary data at IJE online. We also compared indi-
cators of socioeconomic status (SES) for participants
with and without genetic data (Supplementary Table 3,
available as Supplementary data at IJE online).
Results
Sample description
The number of children with genetic data and total IQ
scores was 5300 at 8 years and 3724 at 15 years. The num-
ber of children with educational outcomes was 3990 at
14 years (Key Stage 3) and 6535 at 15 years (Key Stage 4).
Among the 6535 children who sat GCSE examinations,
3977 (61%) children also sat Key Stage 5 examinations.
IQ scores and academic achievement variables were highly
correlated, as described in Supplementary Table 4, avail-
able as Supplementary data at IJE online. A total of 5525
children had genetic data and a SDQ score. Detailed de-
scriptive statistics are provided in Tables 2 and 3. We
found four components to have an eigenvalue above 1 (ad-
justed_ P-value¼ 1.25x10-2). In total, these principal com-
ponents explained 66% of variation in all the outcomes
examined.
Academic achievement
At a SNP inclusion threshold of P 5 x 10-1, there was evi-
dence that a PRS was associated with lower total points at
Key Stage 3 [b: -0.03; 95% confidence interval (CI): -0.05,
-0.003, P¼ 0.03, Table 4] and lower total points at Key
Stage 4 (b: -0.03; 95% CI: -0.05, -0.003, P ¼ 0.03,
Table 4). The direction of effect sizes was similar for SNP
inclusion threshold of P 5x10-2 (Table 4). The evidence
of association when considering only genome-wide signifi-
cant SNPs (P5x10-8) was weak (Table 4). We could not
detect any evidence that a PRS at the examined thresholds
was associated with increased odds of individuals with
GCSE results sitting Key Stage 5 examinations
(Supplementary Table 6, available as Supplementary data
at IJE online).
Cognitive measures
At 8 years and using an SNP inclusion threshold of
P5x10-1, there was strong evidence of a PRS being associ-
ated with lower total IQ (b: -0.04; 95% CI: -0.07, -0.02,
P ¼ 0.002, Table 4) as well as lower verbal (b: -0.04; 95%
CI: -0.07, -0.01, P ¼ 0.003) and performance IQ (b: -0.03;
Table 2. Characteristics of ALSPAC children with available genetic and IQ, or education data
IQ/education measure N % male Mean age in years (SD) Mean score (SD)
IQ at age 8 5300 49.7% 8.6 (0.3) 105.0 (16.4)
IQ at age 15 3724 48.0% 15.4 (0.3) 92.4 (13.1)
Key Stage 3 6029 50.8% 14.1 (0.3) 106.5 (24.3)
Key Stage 4 6535 50.5% 15.0 (0.04) 133.8 (3.8)
Key Stage 5 3990 45.9% 16.3 (0.6) 764.3 (252.7)
ALSPAC, Avon Longitudinal Study of Parents and Children; IQ, intelligence quotient; SD, standard deviation.
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95% CI: -0.06, -0.01, P ¼ 0.01, Supplementary Table 7,
available as Supplementary data at IJE online). The pattern
of results was similar for a threshold of P5x10-2, whereas
the evidence of association when considering only genome-
wide significant SNPs (P5x10-8) was weak (Table 4). At
15 years, we could not detect any evidence of association
between PRS for Alzheimer’s and total IQ or IQ domains,
using either a genome-wide significant SNP threshold or
more liberal SNP inclusion thresholds (Table 4;
Supplementary Table 8, available as Supplementary data
at IJE online). However, the direction of effects was the
same as for age 8, with PRS suggesting lower total IQ (b: -
0.02; 95% CI: -0.05, 0.01, P ¼0.20 at P5x10-1,
Table 4). Also, there was some evidence of association
Table 3. Descriptive statistics for SDQ at age 9
Outcome Range Cut-off indicating problems N N (%) with behavioural problems
Total difficulties 0 to 40 17 5525 246 (4.45%)
Hyperactivity 0 to 10 7 5547 434 (7.82%)
Emotional symptoms 0 to 10 5 5532 349 (6.31%)
Conduct problems 0 to 10 4 5546 378 (6.82%)
Peer problems 0 to 10 4 5541 441 (7.96%)
Prosocial behaviours 0 to 10 6 5553 817 (14.7%)
SDQ, strengths and difficulties questionnaire.
Table 4. Associations between PRS for Alzheimer’s disease and educational, cognitive and behavioural measures
P-value threshold for SNP inclusion
Outcome P¼5 x 10-8 (19 SNPs) P¼5 x 10-2 (45 040) P¼5 x 10-1 (240 803 SNPs)
Educational b (95% CI) P R2 b (95% CI) P R2 b (95% CI) P R2
Key Stage 3 points 0.01 (-0.01, 0.04) 0.33 2.2 x 10-3 0.002 (-0.03, 0.02) 0.87 2.1 x 10-3 0.03 (-0.05, -0.003) 0.03 2.9 x 10-3
Key Stage 4 points 0.001 (-0.02, 0.02) 0.96 3.6 x 10-3 0.01 (-0.04, 0.01) 0.31 3.7 x 10-3 0.03 (-0.05, -0.003) 0.03 4.3 x 10-3
Key Stage 5 points 0.01 (-0.02, 0.04) 0.55 1.6 x 10-3 0.01 (-0.04, 0.02) 0.46 1.6 x 10-3 0.03 (-0.06, 0.003) 0.08 2.2 x 10-3
Cognitive
Total IQ, age 8 0.0002 (-0.03, 0.03) 0.99 2.7 x 10-4 0.03 (-0.06, -0.01) 0.01 1.5 x 10-3 0.04 (-0.07, -0.02) 0.002 2.1 x 10-3
Total IQ, age 15 0.01 (-0.04, 0.02) 0.44 1.3 x 10-3 0.01 (-0.05, 0.02) 0.38 1.3 x 10-3 0.02 (-0.05, 0.01) 0.20 1.5 x 10-3
OR (95% CI) P R2 OR (95% CI) P Pseudo-R2 OR (95% CI) P Pseudo-R2
Behavioural
Total difficulties,
age 9
1.00 (0.89, 1.14) 0.95 5.3 x 10-4 1.02 (0.90, 1.16) 0.78 5.6 x 10-4 1.05 (0.92, 1.19) 0.46 7.9 x 10-4
Prosocial, age 9 0.97 (0.90, 1.04) 0.36 1.4 x 10-3 0.98 (0.91, 1.06) 0.58 1.3 x 10-3 1.00 (0.93, 1.07) 0.95 1.2 x 10-3
Hyperactivity, age 9 0.99 (0.90, 1.09) 0.86 1.3 x 10-3 1.02 (0.92, 1.12) 0.73 1.3 x 10-3 1.05 (0.96. 1.16) 0.29 1.6 x 10-3
Emotional symptoms,
age 9
0.94 (0.84, 1.05) 0.25 2.9 x 10-3 1.00 (0.90, 1.11) 0.96 2.3 x 10-3 1.07 (0.96, 1.19) 0.23 2.9 x 10-3
Conduct problems,
age 9
0.96 (0.86, 1.07) 0.43 9.5 x 10-4 0.99 (0.89, 1.10) 0.88 7.3 x 10-4 1.01 (0.91, 1.13) 0.79 7.5 x 10-4
Peer problems, age 9 1.01 (0.91, 1.11) 0.91 4.5 x 10-4 0.93 (0.85, 1.03) 0.16 1.1 x 10-3 0.97 (0.88, 1.07) 0.53 5.8 x 10-4
Total difficulties,
age 12
1.01 (0.90, 1.14) 0.85 1.7 x 10-3 1.05 (0.93, 1.17) 0.46 2.0 x 10-3 1.04 (0.92, 1.16) 0.56 1.9 x 10-3
Prosocial, age 12 0.93 (0.86, 1.00) 0.05 2.0 x 10-3 1.04 (0.97, 1.13) 0.28 1.4 x 10-3 1.10 (1.02, 1.18) 0.02 2.4 x 10-3
Hyperactivity, age 12 0.97 (0.87, 1.08) 0.56 4.9 x 10-4 1.06 (0.95, 1.18) 0.30 7.7 x 10-4 1.07 (0.96, 1.20) 0.20 1.0 x 10-3
Emotional symptoms,
age 12
1.07 (0.96, 1.20) 0.19 1.4 x 10-3 1.12 (1.00, 1.25) 0.05 2.3 x 10-3 1.16 (1.04, 1.26) 0.01 3.5 x 10-3
Conduct problems,
age 12
0.99 (0.89, 1.10) 0.81 1.6 x 10-3 1.04 (0.94, 1.16) 0.46 1.8 x 10-3 1.05 (0.94, 1.16) 0.42 1.8 x 10-3
Peer problems, age 12 0.96 (0.87, 1.06) 0.43 3.0 x 10-4 0.96 (0.87, 1.06) 0.40 3.3 x 10-4 1.00 (0.91, 1.11) 0.92 9.4 x 10-5
PRS, polygenic risk scores; SNPs, single nucleotide polymorphisms.
Adjusted P-value threshold¼ 0.0125
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between PRS at SNP inclusion thresholds of P5x10-2
with matrix reasoning scores (Supplementary Table 8,
available as Supplementary data at IJE online).
Behavioural difficulties
At all of the examined P-value thresholds, there was weak
evidence that a PRS was associated with the SDQ compo-
nents at 9 years (Supplementary Table 9, available as
Supplementary data at IJE online). At 12 years and an SNP
inclusion threshold P5x10-1, there was some evidence
that a PRS may be associated with the prosocial and emo-
tional score (Table 4). At an SNP inclusion threshold of
P5x10-2, there was evidence of association for a PRS
with higher odds of having an abnormal emotional symp-
toms score (OR: 1.16; 95% CI: 1.04, 1.26, P ¼ 0.01 at
P5x10-1, Table 4). We could not detect any evidence for
association between a PRS at the genome-wide significant
threshold and the SDQ domains.
Sensitivity analysis
The size and direction of effect estimates for PRS excluding
the SNPs within the ApoE gene were similar for most out-
comes (Supplementary Tables 5–10, available as
Supplementary data at IJE online). The direction of effects
and variance explained by the two SNPs tagging the ApoE
region was similar to that explained by the genome-wide
significant PRS (with ApoE) for most outcomes
(Supplementary Tables 5–10, available as Supplementary
data at IJE online). Results for PRS excluding the SNPs as-
sociated with educational attainment at 5x10-8 were simi-
lar to results in the main analysis. When SNPs associated
with educational attainment at P5x10-2 were removed,
evidence of association was attenuated (Supplementary
Tables 11–18, available as Supplementary data at IJE on-
line). In our comparison of participants with and without
genetic data in terms of SES, availability of genetic data
was associated with indicators of SES (Supplementary
Table 3, available as Supplementary data at IJE online).
Discussion
This is one of the first studies investigating whether com-
mon genetic variants predisposing to a higher risk of
Alzheimer’s disease are associated with educational, cogni-
tive and behavioural measures in children from a general
population cohort study. Our findings indicate little evi-
dence for association of the PRS at the genome-wide signif-
icant threshold with cognitive measures, academic
achievement and behavioural difficulties. We found that
PRS at liberal P-value thresholds were associated with
lower academic achievement at 14 and 15 years, as well as
lower total IQ and IQ domain scores at 8 years.
The use of PRS with P-value thresholds of varying
strengths, as well as accounting for genetic variants associ-
ated with educational attainment, allowed for the testing
of three possible mechanisms by which genetic variants for
Alzheimer’s disease may affect the examined outcomes.
The first possibility is that risk variants for Alzheimer’s are
associated with disease protopathology in early life which
manifests as lower IQ and poorer academic achievement in
early life. Lower IQ and poorer academic achievement at
young ages may reduce brain and cognitive reserve, which
could result in reduced ability to tolerate and compensate
for Alzheimer’s disease pathology through structural dif-
ferences in the brain and/or pre-existing cognitive process-
ing approaches/activation of compensatory mechanisms,
respectively known as the brain/cognitive reserve hypothe-
sis33 (Figure 1a). This is not supported by our findings,
since genetic variants most strongly associated with
Alzheimer’s disease (i.e. 5 x 10-8) should also have been as-
sociated with cognitive and educational measures in child-
hood to support this hypothesis. The second possibility is
the presence of horizontal pleiotropy.34,35 SNPs associated
with Alzheimer’s disease could be associated with lower
academic achievement and lower cognitive ability through
biological pathways that are completely unrelated to the
disease (Figure 1b). This could be the case at least for cog-
nitive ability, since evidence of association between the
PRS at liberal thresholds and cognitive ability remained af-
ter the removal of SNPs associated with educational
attainment.
Furthermore, a recent Mendelian randomization study
examining the relationship between intelligence and
Alzheimer’s disease identified some evidence of horizontal
pleiotropy.36 For education, this explanation is not sup-
ported by our findings or by Mendelian randomization
studies,36–38 which indicated a causal effect of education
on Alzheimer’s disease without detecting the presence of
pleiotropy.36,38 The third possibility is the presence of ver-
tical pleiotropy34,35; genetic variants associated with
Alzheimer’s disease are only associated with the disease be-
cause they reduce educational attainment and/or cognitive
ability (Figure 1c). Our findings support this possibility, as
the observed association between PRS for Alzheimer’s dis-
ease and academic achievement is fully attenuated when
the genetic variants associated with educational attainment
are removed.
We did not detect consistent associations between the
PRS at liberal P-value thresholds across all time points
tested. This could be due to either: (i) lower participation
and consequently lower power to detect associations due
to differences in sample size across ages; (ii) varying impact
of environmental factors on behavioural changes across de-
velopment; or (iii) difference in measures.
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Comparison with other studies
In agreement with a previous study showing no effect of
ApoE on cognitive outcomes in ALSPAC children, we did
not find any evidence that the genome-wide significant PRS
was associated with cognition.39 A recent study40 in children
and adolescents from two independent cohorts in Brazil
(N¼ 716) found that a PRS for Alzheimer’s disease was as-
sociated with lower scores in non-declarative memory exer-
cises at P 0.01 and with reading and writing at more
liberal P-value thresholds. They did not find strong evidence
for cognitive tasks or brain structure in a comparable sample
of adolescents (N¼ 1029, mean age 15 years). Our findings
are also in agreement with those from adult populations for
which there is an established association between a PRS for
Alzheimer’s disease and adverse cognitive outcomes.15,16 In
adults from the UK Biobank, there is an association between
a higher PRS for Alzheimer’s disease with lower cognitive
performance (P1x10-2) and educational attainment
(P5x10-2).16 Furthermore, a phenome-wide analysis41 us-
ing linkage disequilibrium score regression showed negative
genetic correlations between Alzheimer’s disease and cogni-
tive outcomes. In line with our findings, this study did not
detect associations between a PRS for Alzheimer’s disease at
P 0.30 and different SDQ components.
Strengths and limitations
Our study benefits from using a large discovery GWAS
of individuals with a clinical diagnosis of late-onset
Alzheimer’s and a large sample of children representative
of the population as a target sample. Our study differs
from many earlier studies, in that we used academic
achievement on a continuous scale, rather than educational
attainment which is traditionally measured on a categori-
cal scale. Thus, our results are far more precise and poten-
tially very well powered to pick up effects. The use of the
PRS in children allowed us to perform this investigation
without the selection bias present in late life studies.
The inherent limitation of using PRS is the limited
amount of phenotypic variance they explain, which is also
true for this study (<1%). Genome-wide complex trait
analysis has shown that variants achieving genome-wide
significance for Alzheimer’s currently explain only 16.3%
of phenotypic variance. When all SNPs in the dataset are
Cognitive ability/academic 
achievement
SNPs for AD
(a)
(b)
(c)
Academic 
achievement/cognitive ability
AD
AD
Cognitive reserve hypothesis
AD protopathology
SNPs for AD
Horizontal pleiotropy
Cognitive abilitySNPs for AD
Vertical pleiotropy
Academic achievement AD
Figure 1. Potential mechanisms of associations between PRS for Alzheimer’s disease and cognitive ability/academic achievement. Please note that
these are not intended to be directed acyclic graphs. AD denotes Alzheimer’s disease. In panel (a), genetic variants for Alzheimer’s disease cause
Alzheimer’s disease protopathology, which manifests as lower IQ and poorer academic achievement at young ages. This could result in reduced abil-
ity to tolerate and compensate for Alzheimer’s disease pathology. Panel (b) describes the situation where genetic variants that increase predisposi-
tion for Alzheimer’s disease affect academic achievement and/or cognitive ability through an independent pathway (horizontal pleiotropy). In panel
(c), genetic variants used to instrument Alzheimer’s disease have their primary effect on Alzheimer’s disease through academic achievement and/or
cognitive ability rather than vice versa.
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included, the amount of phenotypic variance explained
increases to 53.2%.42 We used a more liberal threshold for
SNP inclusion than that of genome-wide significance
because, although it might introduce noise,43 it increases
power to detect individuals at highest/lowest risk.9
Another limitation of this study could be the differential
attrition or non-participation by PRS, which has been
shown to introduce collider bias into studies for psychiatric
disorders. A recent study in addressing the issue of selec-
tion bias in genetic studies did not detect evidence for
an association between PRS for Alzheimer’s disease and
non-participation in ALSPAC.44
Our study is the first to examine the association be-
tween genetic variants for Alzheimer’s disease and both ed-
ucational, cognitive and behavioural outcomes in
childhood and adolescence in such a large sample. We
show with great precision that individuals with substan-
tially increased risk of Alzheimer’s disease later in life have
similar educational attainment to other individuals in the
population. This suggests that the risk factors for
Alzheimer’s disease play a role after adolescence.
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Supplementary data are available at IJE online.
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